Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
no estimate extracted
2 participants
GRADE not reported
Metformin Diagnostic criteria: 2 studies applied the WHO 1999 criteria for 'prediabetes' (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a; Zeng 2013) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy showed no clear difference in metformin Diagnostic criteria: 2 studies applied the WHO 1999… compared with another pharmacological glucose‐lowering monotherapy (low certainty).
1 finding from 1 review
Acarbose Diagnostic criteria: 1 study applied the WHO 1999 criteria for prediabetes (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Repaglinide Diagnostic criteria: 1 study applied the ADA 2010 criteria (FPG ≥ 5.6 mmol/L and < 6.9 mmol/L and 2‐h glucose ≥ 7.8 mmol/L or < 11.0 mmol/L after a 75 g OGTT; Zhang 2007) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: headache · women with heavy menstrual bleeding
Progestogen therapy long cycle (3 to 4 weeks) showed no clear difference in adverse effect Headache compared with other medical therapy (low certainty).
1 finding from 1 review
Adverse effect Breakthrough bleeding/spotting · women with heavy menstrual bleeding
Progestogen therapy long cycle (3 to 4 weeks) may leads to lower adverse effect Breakthrough bleeding/spotting compared with other medical therapy (low certainty).
1 finding from 1 review
Menstrual blood loss PBAC score · women with heavy menstrual bleeding
2 findings from 1 review
Satisfaction · women with heavy menstrual bleeding
Progestogen therapy long cycle (3 to 4 weeks) may leads to lower satisfaction compared with other medical therapy (low certainty).
1 finding from 1 review
Days of bleeding · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in vertigo frequency · Ménière’s disease
Positive pressure therapy showed no clear difference in improvement in vertigo frequency compared with placebo (low certainty).
1 finding from 1 review
Change in vertigo (global score) · Ménière’s disease
1 finding from 1 review
Change in vertigo frequency · Ménière’s disease
1 finding from 1 review
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · high‐grade glioma
Daily conventionally fractionated radiotherapy probably leads to higher overall survival compared with no radiotherapy (supportive care alone) (moderate certainty).
1 finding from 1 review
Adverse effects · high‐grade glioma
1 finding from 1 review
Progression‐free survival · high‐grade glioma
1 finding from 1 review
Quality of life · high‐grade glioma
1 finding from 1 review